MBCProject_0943_T1_RNA
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.430
- PROTEIN_SECRETION+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- ANGIOGENESIS+0.290
- MYC_TARGETS_V1+0.280
- HEDGEHOG_SIGNALING+0.210
- ESTROGEN_RESPONSE_EARLY+0.190
- E2F_TARGETS+0.150
- UV_RESPONSE_DN+0.150
- OXIDATIVE_PHOSPHORYLATION+0.140
Top 10 suppressed
- MYC_TARGETS_V2-0.350
- HYPOXIA-0.340
- ALLOGRAFT_REJECTION-0.330
- INTERFERON_GAMMA_RESPONSE-0.310
- KRAS_SIGNALING_DN-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- INFLAMMATORY_RESPONSE-0.290
- INTERFERON_ALPHA_RESPONSE-0.280
- ADIPOGENESIS-0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0WT-01A-11R-A109-07 | — | B | 0.732 |
| 2 | TCGA-BH-A1ES-01A-11R-A137-07 | — | B | 0.729 |
| 3 | TCGA-AR-A24L-01A-11R-A169-07 | — | B | 0.711 |
| 4 | SRR25617938 | — | B | 0.695 |
| 5 | TCGA-B6-A0IM-01A-11R-A034-07 | — | B | 0.686 |
| 6 | TCGA-BH-A204-01A-11R-A157-07 | — | B | 0.666 |
| 7 | TCGA-33-4533-01A-01R-1201-07 | — | cohortMD1 | 0.660 |
| 8 | ERR2598214 | fetal | fetal | 0.660 |
| 9 | TCGA-BH-A1FM-01A-11R-A13Q-07 | — | B | 0.652 |
| 10 | SRR25617914 | — | C | 0.650 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.070 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |